TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism
Brief Summary: We propose a study which will combine multiple modalities in evaluating the treatment response of children with autism spectrum disorders (ASD) to acetyl-choline esterase (AChE) inhibitors and choline supplements. The primary objective of the study is to examine the efficacy of this treatment in improving core autistic symptoms. The Secondary objective of the study is to evaluate the safety and tolerability of the treatment protocol in ASD children. Exploratory objectives include evaluation of the influence of the treatment on linguistic performance, comorbid behaviors, adaptive functioning and executive functions.


Options:
A: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline
C: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
D: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism
Brief Summary: We propose a study which will combine multiple modalities in evaluating the treatment response of children with autism spectrum disorders (ASD) to acetyl-choline esterase (AChE) inhibitors and choline supplements. The primary objective of the study is to examine the efficacy of this treatment in improving core autistic symptoms. The Secondary objective of the study is to evaluate the safety and tolerability of the treatment protocol in ASD children. Exploratory objectives include evaluation of the influence of the treatment on linguistic performance, comorbid behaviors, adaptive functioning and executive functions.


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE
Brief Summary: Numerous human cardiac stem cell studies have been published, including relatively small number of patients. Meta-analysis of randomized trials have reported safety and a 3-6% increase in global left ventricular performance after intracoronary stem cell therapy in patients with acute myocardial infarction. Since most of the studies used different type of stem cells, delivery modes, and patient population, the results are heterogenous, therefore the comparison of the results is biased regarding generalizable conclusions about the effect of treatment. The present comparative meta-analysis is based on individual patient data, and gathers and pools the raw data, and analyzes the clinical outcome, safety and efficacy of the cardiac stem cell therapy.


Options:
A: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Biological: Auto-CD34+ cells | Arm Label: Active Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Diluent used to suspend Auto-CD34+ cells | Arm Label: Unblinded Standard of Care (SOC) Arm; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: BIOLOGICAL; Name: Auto-CD34+ cells; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Placebo: Diluent used to suspend Auto-CD34+ cells; Assigned to Arm(s): Active Control Arm | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Unblinded Standard of Care (SOC) Arm
B: Arm Label: Intramyocardial injection of BM cells; Type: EXPERIMENTAL; Interventions: Other: intramyocardial injection of BM cells | Arm Label: Intramyocardial / intracoronary injection of BM cells; Type: EXPERIMENTAL; Interventions: Other: intramyocardial / intracoronary injection of BM cells | Arm Label: control; Type: OTHER; Interventions: Other: Best medical therapy | Intervention Type: OTHER; Name: intramyocardial injection of BM cells; Assigned to Arm(s): Intramyocardial injection of BM cells | Intervention Type: OTHER; Name: intramyocardial / intracoronary injection of BM cells; Assigned to Arm(s): Intramyocardial / intracoronary injection of BM cells | Intervention Type: OTHER; Name: Best medical therapy; Assigned to Arm(s): control
C: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Sham, no injection | Arm Label: C3BS-CQR-1 Treated; Type: EXPERIMENTAL; Interventions: Biological: Injection of C3BS-CQR-1 | Intervention Type: BIOLOGICAL; Name: Injection of C3BS-CQR-1; Assigned to Arm(s): C3BS-CQR-1 Treated | Intervention Type: BIOLOGICAL; Name: Sham, no injection; Assigned to Arm(s): Control
D: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE
Brief Summary: Numerous human cardiac stem cell studies have been published, including relatively small number of patients. Meta-analysis of randomized trials have reported safety and a 3-6% increase in global left ventricular performance after intracoronary stem cell therapy in patients with acute myocardial infarction. Since most of the studies used different type of stem cells, delivery modes, and patient population, the results are heterogenous, therefore the comparison of the results is biased regarding generalizable conclusions about the effect of treatment. The present comparative meta-analysis is based on individual patient data, and gathers and pools the raw data, and analyzes the clinical outcome, safety and efficacy of the cardiac stem cell therapy.


Options:
A: Arm Label: The treatment group; Type: EXPERIMENTAL; Interventions: Procedure: Intracoronary injection of autologous bone marrow mononuclear cells | Arm Label: the control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Intracoronary injection of autologous bone marrow mononuclear cells; Assigned to Arm(s): The treatment group
B: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group
C: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Intra-coronary infusion | Intervention Type: DRUG; Name: Intra-coronary infusion; Assigned to Arm(s): Treatment Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma
Brief Summary: RATIONALE: Observation is watching a patient's condition but not giving treatment unless symptoms appear or change. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is not yet known whether observation or lenalidomide is more effective in treating patients who are in complete or partial response after receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for cutaneous T-cell lymphoma or mycosis fungoides/Sézary syndrome.

PURPOSE: This randomized phase III trial is studying observation to see how well it works compared with lenalidomide in treating patients who are in complete or partial response after receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for stage IIB, stage III, or stage IV cutaneous T-cell lymphoma or stage IIB, stage III, or stage IV mycosis fungoides/Sézary syndrome.


Options:
A: Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide
B: Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): N/A
C: Arm Label: Caelyx; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin hydrochloride | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): Caelyx
D: Arm Label: KW-0761; Type: EXPERIMENTAL; Interventions: Biological: KW-0761 | Arm Label: Vorinostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vorinostat | Intervention Type: BIOLOGICAL; Name: KW-0761; Assigned to Arm(s): KW-0761 | Intervention Type: DRUG; Name: Vorinostat; Assigned to Arm(s): Vorinostat

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blinded, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Topically Applied 1.0% WBI-1001 Cream for 12 Weeks, in the Treatment of Mild to Moderate Plaque Psoriasis.
Brief Summary: Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin. This study, in patients with mild to moderate plaque psoriasis, is designed to further determine the efficacy, safety and tolerability of the novel, topically applied, non-steroid, anti-inflammatory WBI-1001 cream over a period of 12 weeks.


Options:
A: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: WBI-1001 | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: WBI-1001 | Intervention Type: DRUG; Name: WBI-1001; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LCD | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcipotriol | Intervention Type: DRUG; Name: LCD; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: calcipotriol; Assigned to Arm(s): 2
C: Arm Label: U0267 foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 Foam | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle foam | Intervention Type: DRUG; Name: U0267 Foam; Assigned to Arm(s): U0267 foam | Intervention Type: DRUG; Name: Vehicle foam; Assigned to Arm(s): Vehicle foam
D: Intervention Type: DRUG; Name: Calcipotriol plus betamethasone dipropionate (LEO80185 gel); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial on the Effect of Intermittent Pedicle Clamping Using 15 or 30 Minutes Ischemic Intervals During Liver Surgery
Brief Summary: In order to prevent excessive blood loss during liver surgery, an intermittent Pringle manoeuvre (IPM) can be applied. This implies a temporary clamping of the portal vein and hepatic artery in the hepatoduodenal ligament in order to occlude hepatic inflow. The optimal duration of the IPM is unknown. This randomized controlled trial aimed to analyse differences in hepatocellular damage after 15 minutes or 30 minutes IPM during liver surgery for primary or secondary liver tumours.


Options:
A: Intervention Type: DRUG; Name: FOLFOX regimen; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rThrombin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: bovine thrombin | Intervention Type: BIOLOGICAL; Name: rThrombin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bovine thrombin; Assigned to Arm(s): 2
C: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
D: Arm Label: Pringle manoeuvre 15 minutes; Type: EXPERIMENTAL; Interventions: Procedure: Pringle manoeuvre 15 minutes | Arm Label: Pringle manoeuvre 30 minutes; Type: EXPERIMENTAL; Interventions: Procedure: Pringle manoeuvre 30 minutes | Intervention Type: PROCEDURE; Name: Pringle manoeuvre 15 minutes; Assigned to Arm(s): Pringle manoeuvre 15 minutes | Intervention Type: PROCEDURE; Name: Pringle manoeuvre 30 minutes; Assigned to Arm(s): Pringle manoeuvre 30 minutes

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxepa in Multiple Trauma: Prospective, Randomized, Comparative, Double-blind, Controlled Clinical Study
Brief Summary: This is a single-center, prospective, randomized, comparative, double-blind controlled clinical study mend to assess the effect of enteral feeding with Oxepa (a fish oil-based nutrition), compared to an isocaloric control, on oxygenation and clinical outcomes in mechanically ventilated trauma patients.

The study population will be adults admitted to the ICU due to multiple-trauma or head trauma as a result of a gun shut, motor vehicle accidents, fall, workplace accident etc.


Options:
A: Arm Label: Oxepa; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding., Dietary Supplement: oxepa | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: oxepa; Assigned to Arm(s): Oxepa | Intervention Type: DIETARY_SUPPLEMENT; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Lanicemine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanicemine; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: HCORT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): HCORT
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sertraline; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A comparator study to assess safety and efficacy of Flutiform® compared with symbicort turbohaler in asthma patients with moderate to severe persistent, reversible asthma.


Options:
A: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
B: Arm Label: Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flutiform, Drug: Symbicort Turbohaler | Arm Label: inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort Turbohaler | Intervention Type: DRUG; Name: Flutiform; Assigned to Arm(s): Inhaler | Intervention Type: DRUG; Name: Symbicort Turbohaler; Assigned to Arm(s): Inhaler, inhaler
C: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 1
D: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increasing CRC Screening in Primary Care Settings
Brief Summary: Colorectal cancer screening remains lower than optimal. The purpose of this study was to test the efficacy of phone-based motivational interviewing versus tailored communication versus usual care in increasing CRC screening in primary care clinics.


Options:
A: Arm Label: Prevention Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention Care Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention Care Management; Assigned to Arm(s): Prevention Care Management
B: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A
D: Arm Label: lifestyle counseling tailored; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored counseling | Arm Label: lifestyle counseling motivational; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored counseling; Assigned to Arm(s): lifestyle counseling tailored | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): lifestyle counseling motivational

Answer: D